OBJECTIVE:To enhance the level of rational use of drug in hospitals.METHODS:The rational use of drug software system-Prescription Automatic Screening System(PASS)was installed and operated at doctor workstation,clinic pharmaceutical workstation and inpatient pharmacy including the intravenous drugs distribution center,where also nested with the patients'information consulting system;the function of information confirmation about the quantity and kinds of drugs was developed as well so as to share data in the PASS and hospital information system,and construct a computer network sys?tem of rational use of drug in the clinic,also be used in the clinic.RESULTS:The network of rational use of drug provided an effective means for instructing and monitoring use of drug in the clinic.CONCLUSION:Developing digital computer means for the pharmacy services in the clinic is practicable and effective.

OBJECTIVE: To probe into the standardized management of dispensing in the pharmacy METHODS: To introduce the idea of standardization in dispensing, to establish and implement SOP(standard operating procedure), to carry out networking management, to setup the modern facility, and to introduce the new open and divisional mode for dispensing drugs and to put dispensing and supply of drugs in over - inclusive standardized management .RESULTS: The standardized management of dispensing and supply of drugs was achieved on the whole and the aim of precise dispensing and scientific management was fulfilled. CONCLUSION: The establishment and implementation of SOP, the networking management of drugs and mord-ernization of facility are the basis of standardization of dispensing of drugs.

OBJECTIVE:To evaluate the cost and effectiveness of three pharmacotherapeutic schemes for hemorrhage of upper digestive tract caused by liver cirrhosis.METHODS:132 patients with hemorrhage of upper digestive tract were treated by different drugs:octreotide(49),somatostatin(42),pituitrin(41).Evaluation was carried out with pharmacoeconomic cost-ef_fectiveness analysis.RESULTS:The hemostatic rates of octreotide,somatostatin and pituitrin for rupture of esophageal varicosis were 88.89%,80% and 46.15%;for peptic ulcer bleeding associated with liver cirrhosis 88.89%,87.50% and 50.00% and for hemorrhage from acute gastric mucosa erosion combined with liver cirrhosis 100.00%,94.44% and 68.18%,respectively.The costs of octreotide,somatostatin and pituitrin schemes were RMB 2 242.8,3 294 and 996.2 yuans,respectively.CONCLU_SION:According to the evaluation with pharmacoeconomic cost-effectiveness analysis,the therapeutic scheme of pituitrin seems to be the best one for treating hemorrhage of upper digestive tract resulting from liver cirrhosis.

Objective: To establish the identificational method of Compound Biejiaruangan Tablets. Methods: The microscopic identification and TLC were used. Results: Carapax Trionycis, Radix Paeoniae Rubra, Radix Notoginseng, Placenta Hominis, and Cordyceps in Compound Biejiaruangan Tablets can be distinguished by microscopic identification and Cordyceps, Fructus Forsythiae and Radix Notoginseng can be identified by TLC, respectively. Conclusion: This method is simple, rapid and with a good reappearance, and available for quality control of the preparation.

Breast cancer stem cells (CSCs) are the main causes leading to the failure of treatment of breast cancer and play important roles in the progression of breast cancer and drug resistance, which are closely related to the therapeutic resistance of radiotherapy and chemotherapy, and endocrine therapy.The metastatic potential and therapeutic resistance of CSCs are associated with epithelial mesenchymal transition and Hedgehog, Wnt, interleukin-6/signal transduction and tanscriptional activation factor 3, transforming growth factor-β and other signaling pathways.While some of the targeted drugs targeting these signaling pathways are undergoing clinical transformation, which is expected to provide new approach for the clinical treatment of breast cancer.

OBJECTIVE　To study the pharmacokinetics of omeprazole (OME) in 8 patients with liver cirrhosis.METHODS　The plasma concentrations of OME were determined by HPLC,and the pharmacokinetic parameters were computed by using 3P97 program.RESULTS　The plasma concentration versus time curve following intravenous 40 mg OME in patients with liver cirrhosis was coincident with two-compartment model.The elimination half-life was (3.34±0.38) h,which was longer than the value of the healthy volunteers and CLs was lower than the value of the healthy volunteers.CONCLUSION　The dosage of OME may be given in the half of the routine dosage or adjusted conditionally when using for the patients with liver cirrhosis.

Objective To verify the clinical effect of Qinghuang powder in chronic myelogenous leukemia(CML). Methods 86 CML patients treated with Qinghuang powder, in which 28 cases also partially received herbal medicine (activating blood circulation to dissipate blood stasis). Results 62 cases had complete remission (72.1%), 14 cases partial remission (16.3 %), advance 8 cases(9.3 %), inefficiency 2 cases (2.3 %), and the total efficiency was 97.7 %. The symptom were improved after a week when patients had taken medicines. 44 cases have hepatomegalia, among them 39 cases have diminished or became normal compared to untreated. 70 cases have splenoparectasis, among them 60 cases became normal, 9 cases diminished, and 1 case had no change after treatment. It took 15.5 days in average when spleen began to diminish, and took 62.9 days to become smallest. The WBC began to decrease at 10.4 day and took 54.8 days in average became normal. The major side effect was digestive tract symptom, followed by skin pigmentation and skin excessive cornification. It could be avoided by low dosage. Conclusion Qinghuang powder could not only induce CML to CR, but also improve the clinical symptom of CML and eliminate the infiltration of leukemia cells. It has little influence to Hb and Plt.

OBJECTIVETo evaluate the strategy for management of urosepsis after extracorporeal shock wave lithotripsy (ESWL).

METHODSThe clinical data were analyzed in 4 cases of urosepsis caused by ESWL during the period from January, 2008 to October 2011.

RESULTSTwo of the patients had kidney stones and two had ureteral stones. Analysis of urine bacterial culture revealed the presence of E. coli in 2 cases, Klebsiella pneumoniae in 1 case and Pseudomonas putida combined E. coli in 1 case. All the 4 patients were monitored for ECG, blood pressure and oxygen saturation, and received fluid replacement and anti-inflammatory therapy. The vital signs of the patients became stable after 5-11 days (mean 6.75 days). Three patients underwent ureteroscopic lithotripsy, and 1 patient had emergency ureteral stent indwelling. All the 4 patients were cured and discharged.

CONCLUSIONESWL is more likely to cause urosepsis in patients with ureteral stones and urinary infection, for which early nonsurgical interventions should be administered immediately after the diagnosis is established.

Adult ; Female ; Humans ; Lithotripsy ; adverse effects ; Male ; Middle Aged ; Retrospective Studies ; Sepsis ; etiology ; therapy ; Ureteral Calculi ; therapy ; Urinary Tract Infections ; etiology ; therapy

Objective To explore the expression of S100A14 in breast cancer tissue, and the EGF and S100A14 feedback regulatory mechanism. Methods S100A14 mRNA level in 52 cases of of breast cancer and adjacent normal tissue was detected by quantitative real?time PCR. S100A14 protein in 21 cases of breast cancer and adjacent normal tissue was detected by Western blot. S100A14 mRNA after EGF treatment was detected by RT?PCR and real?time PCR. The levels of S100A14, p?ERK and t?ERK were detected by Western blot. Knocking down S100A14 expression was performed by siRNA technology. Results The levels of S100A14 mRNA and protein were significantly increased in breast cancer tissues ( P<0.05 for both) . The high expression of S100A14 was related with the recurrence of breast cancer patients ( P=0.038). S100A14 mRNA level was significantly up?regulated in the MDA?MB?453 cells (1.50±0.11) and MCF?7 cells (1.40±0.03) after 1 ng/mL EGF treatment, and 1.66±0.08 and 1.71±0.17 in the MDA?MB?453 cells after 10 ng/mL EGF treatment, significantly higher than that of the control group (1.00±0.09 and 1.00±0.03) (P<0.05 for both). In the TD47 cells, the S100A14 mRNA levels in the control, 1 ng/ml EGF and 10 ng/ml EGF + U0126 treatment groups were 1. 00 ± 0. 04, 1. 56 ± 0. 04 and 1. 00 ± 0. 10, respectively ( P<0.05) . Conclusions The expression of S100A14 mRNA and protein is promoted by EGF through p? ERK signaling pathway in breast cancer cells. There may be a feedback loop between EGF and S100A14.

Objective To explore the expression of S100A14 in breast cancer tissue, and the EGF and S100A14 feedback regulatory mechanism. Methods S100A14 mRNA level in 52 cases of of breast cancer and adjacent normal tissue was detected by quantitative real?time PCR. S100A14 protein in 21 cases of breast cancer and adjacent normal tissue was detected by Western blot. S100A14 mRNA after EGF treatment was detected by RT?PCR and real?time PCR. The levels of S100A14, p?ERK and t?ERK were detected by Western blot. Knocking down S100A14 expression was performed by siRNA technology. Results The levels of S100A14 mRNA and protein were significantly increased in breast cancer tissues ( P<0.05 for both) . The high expression of S100A14 was related with the recurrence of breast cancer patients ( P=0.038). S100A14 mRNA level was significantly up?regulated in the MDA?MB?453 cells (1.50±0.11) and MCF?7 cells (1.40±0.03) after 1 ng/mL EGF treatment, and 1.66±0.08 and 1.71±0.17 in the MDA?MB?453 cells after 10 ng/mL EGF treatment, significantly higher than that of the control group (1.00±0.09 and 1.00±0.03) (P<0.05 for both). In the TD47 cells, the S100A14 mRNA levels in the control, 1 ng/ml EGF and 10 ng/ml EGF + U0126 treatment groups were 1. 00 ± 0. 04, 1. 56 ± 0. 04 and 1. 00 ± 0. 10, respectively ( P<0.05) . Conclusions The expression of S100A14 mRNA and protein is promoted by EGF through p? ERK signaling pathway in breast cancer cells. There may be a feedback loop between EGF and S100A14.